<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368757</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_CMML 1</org_study_id>
    <secondary_id>2009-017147-33</secondary_id>
    <nct_id>NCT01368757</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Patients With Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a phase I study the investigators plan to investigate safety and toxicity of lenalidomide
      in patients with Chronic Myelomonocytic Leukemia (CMML). A phase II study will be started
      once an optimal dose has been found. The primary endpoint will concern the efficacy of
      lenalidomide in patients with CMML according to the WHO diagnostic criteria.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>2 years</time_frame>
    <description>This is a phase I/II, open-label, dose-escalation study of lenalidomide in patients with CMML. In phase I of the study the primary purpose is to determine the MTD. The purpose of phase II is to determine the response rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and seriousness of adverse events to evaluate safety and tolerability</measure>
    <time_frame>4 years</time_frame>
    <description>For both phases (phase I and II), secondary objectives are to evaluate safety, tolerability, efficacy and analysis of molecular markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving transfusion independence</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients achieving cytogenetic response</measure>
    <time_frame>4 years</time_frame>
    <description>Phase II; Cytogenetic response assessment requires 20 analyzable metaphases using conventional cytogenetic techniques, FISH may be used an a supplement to follow a specifically defined cytogenetic abnormality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revlimid</intervention_name>
    <description>Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients
The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.
Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen.</description>
    <other_name>lenalidomide</other_name>
    <other_name>lenalidomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CMML according to the WHO diagnostic criteria.

          2. Understand and voluntarily sign an informed consent form.

          3. Age &gt;=18 years at the time of signing the informed consent form.

          4. Able to adhere to the study visit schedule and other protocol requirements.

          5. All previous cancer therapy must have been discontinued at least 4 weeks prior to
             treatment in this study. Patients carrying a somatic mutation involving the platelet
             derived growth factor receptor beta (PDGFRB) can be included if standard treatment
             with imatinib failed.

          6. ECOG performance status of &lt;= 2 at study entry.

          7. Laboratory test results within these ranges:

               -  Creatinine clearance &gt; 30ml/min

               -  AST (SGOT) and ALT (SGPT) &lt;= 2.5 x ULN

          8. Disease free of prior malignancies for &gt;= 5 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix
             or breast.

          9. Female subjects of childbearing potential must:

               -  Understand the study drug is expected to have a teratogenic risk

               -  Agree to use two effective contraception

         10. Male subjects must

               -  Agree to use condoms

               -  Agree not to donate semen

         11. All subjects must

               -  Agree to abstain from donating blood

               -  Agree not to share study drug with another person

        Exclusion Criteria:

          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking lenalidomide).

          3. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          4. Use of any other experimental drug or therapy within 28 days of baseline.

          5. Known hypersensitivity to thalidomide.

          6. The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          7. Any prior use of lenalidomide.

          8. Concurrent use of other anti-cancer agents or treatments.

          9. Known positive for HIV or infectious hepatitis, type A, B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Thaler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Wels-Grieskirchen GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonja Burgstaller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Wels-Grieskirchen GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus d. Barmherzigen Schwestern Linz, Interne I</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen Linz GmbH, 1. Interne</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik f. Innere Medizin Graz, Klinische Abteilung f. Hämatologie</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch, Interne E</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik der PMU Salzburg, UK f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUW/ AKH Wien Univ. Klinik für Innere Medizin I, Abteilung für Hämatologie und Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus, 3. Med. Abtlg. Für Hämatologie und Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Richard Greil</name_title>
    <organization>Arbeitsgemeinschaft medikamentoese Tumortherapie</organization>
  </responsible_party>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

